No Data
No Data
What Shenzhen Bioeasy Biotechnology Co., Ltd.'s (SZSE:300942) P/S Is Not Telling You
Yirui Biotechnology (300942.SZ): The company's in vitro diagnostic business has greatly shrunk. Currently, the company is focusing on steady development of the food safety rapid detection business.
Yirui Biology (300942.SZ) stated on its investor platform on July 16th that its in vitro diagnostic business has greatly shrunk, and the company is currently focusing on the steady development of its food safety rapid detection business. The main reason for the loss in the first quarter was the shrinkage of the in vitro diagnostic business and the influence of seasonal factors on the income of the food safety business, but the corresponding fixed costs such as rent and personnel wages remained at a certain level.
Yirui Biological (300942.SZ): The concerted action person of the actual controller plans to reduce the shareholding by a total of no more than 735,800 shares.
On June 13th, Gelunhui reported that Yirui Biology (300942.SZ) announced that the company's controlling shareholder and actual controller's consistent action person, Shenzhen Yida Rui Management Consulting Partnership Enterprise (Limited Partnership) (hereinafter referred to as 'Yida Rui') and Shenzhen Yikai Rui Management Consulting Partnership Enterprise (Limited Partnership) (hereinafter referred to as 'Yikai Rui') plan to reduce their holdings of company shares through centralized bidding or bulk trading within three months (from July 5th, 2024 to October 4th, 2024) after 15 trading days from the date of announcement disclosure. The specific details are as follows: 1. Holds 19,762,903 shares of the company (accounting for
Private Companies Are Shenzhen Bioeasy Biotechnology Co., Ltd.'s (SZSE:300942) Biggest Owners and Were Hit After Market Cap Dropped CN¥397m
Yi Rui Biotech (300942.SZ): Financial director changed to Wang Guangsheng
Gelonghui, May 24, 丨 Yi Rui Biotech (300942.SZ) announced that the company's board of directors recently received the resignation report from Mr. Wan Kai, the company's financial director. Mr. Wan Kai applied to resign as the company's financial director due to personal reasons. The original term was from April 1, 2024 to March 31, 2027. After his resignation, he no longer held any position in the company. Nominated by the company's general manager, approved by the board nomination committee's qualification review, and reviewed and approved by the board audit committee, the board of directors agreed to appoint Mr. Wang Guangsheng as the company's financial director. The term of office begins on the date of review and approval by the board of directors until the end of the third board of directors of the company
The controlling shareholder, actual controller and co-actors of Yirui Biotech (300942.SZ) intend to transfer 6.59% of the shares by agreement
Yi Rui Biotech (300942.SZ) announced that the controlling shareholder of the company, Yi Rui (Hainan) Venture Capital Co., Ltd. (“Easy...
No Data